Orion OYJ Q3 2024 Earnings Report

Orion OYJ EPS Results

• Actual EPS: $0.63
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Orion OYJ Revenue Results

• Actual Revenue: $517.97 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Orion OYJ Announcement Details

• Quarter: Q3 2024
• Date: 10/29/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Orion Corporation (Orion OYJ (OTCMKTS:ORINY)) is a Finland-based pharmaceutical company engaged in the research, development, manufacture and marketing of human and veterinary medicines as well as diagnostic tests. The company’s core therapeutic areas include central nervous system disorders, oncology and respiratory diseases, and it offers both proprietary and generic products. Orion’s product range spans from small-molecule drugs and active pharmaceutical ingredients to radiodiagnostic imaging agents and line extensions developed through in-house research.

Since its founding in 1917 in Helsinki, Orion has grown into an integrated pharmaceuticals business with state-of-the-art manufacturing facilities in Finland and France. The company’s R&D organization focuses on novel chemical entities and life-cycle management of existing products, supported by a network of research partnerships and licensing agreements. In addition to human healthcare, Orion Diagnostica develops and distributes immunoassays and point-of-care tests for clinical and veterinary diagnostics.

Orion serves markets across Europe, the Nordic countries and selected regions in Asia and Latin America, leveraging both direct sales operations and partner networks. The company maintains strategic alliances to expand its geographic reach and enhance market access for its specialty products. Orion’s customer base includes hospitals, pharmacies and healthcare professionals, reflecting its long-established presence in the pharmaceutical industry.